0001104659-21-085705.txt : 20210728 0001104659-21-085705.hdr.sgml : 20210728 20210625160524 ACCESSION NUMBER: 0001104659-21-085705 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210625 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc. CENTRAL INDEX KEY: 0001798749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831377888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 200 BERKELEY STREET STREET 2: FLOOR 18 CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617-443-2400 MAIL ADDRESS: STREET 1: 200 BERKELEY STREET STREET 2: FLOOR 18 CITY: BOSTON STATE: MA ZIP: 02116 CORRESP 1 filename1.htm

VIA EDGAR

June 25, 2021

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn:	Kasey Robinson
	Christopher Edwards

Re:	Aerovate Therapeutics, Inc.
	Acceleration Request for Registration Statement on Form S-1
	File No. 333-256949

	Requested Date:	June 29, 2021
	Requested Time:	4:30 p.m. Eastern Standard Time

Dear Ms. Robinson and Mr. Edwards:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Jefferies LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters, hereby join Aerovate Therapeutics, Inc. in requesting that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to June 29, 2021, at 4:30 p.m., Eastern Time, or as soon thereafter as practicable.

Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.

[Signature Page Follows]

Very truly yours,

As representatives of the several underwriters

JEFFERIES LLC

By:	/s/ Matthew Kim
	Name:Matthew Kim
	Title:Managing Director, Joint Head of US Biotechnology

COWEN AND COMPANY, LLC

By:	/s/ Bill Follis
	Name:Bill Follis
	Title:Managing Director

EVERCORE GROUP L.L.C.

By:	/s/ Maren Winnick
	Name:Maren Winnick
	Title:Senior Managing Director, Advisory